{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T04:31:11Z","timestamp":1719981071861},"reference-count":24,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T00:00:00Z","timestamp":1496793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ymgme.2017.06.001","type":"journal-article","created":{"date-parts":[[2017,6,3]],"date-time":"2017-06-03T23:16:38Z","timestamp":1496531798000},"page":"92-99","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report"],"prefix":"10.1016","volume":"122","author":[{"given":"Sarah","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chester B.","family":"Whitley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanine R.","family":"Jarnes Utz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2017.06.001_bb0005","series-title":"Pediatric Endocrinology and Inborn Errors of Metabolism","first-page":"731","author":"Sarafoglou","year":"2009"},{"key":"10.1016\/j.ymgme.2017.06.001_bb0010","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1542\/peds.2007-1350","article-title":"Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome)","volume":"121","author":"Martin","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2017.06.001_bb0015","unstructured":"M. Scarpa, Mucopolysaccharidosis type II, in: R.A. Pagon, M.P. Adam, H.H. Ardinger, S.E. Wallace, A. Amemiya, L.J.H. Bean, T.D. Bird, N. Ledbetter, H.C. Mefford, R.J.H. Smith, K. Stephens (Eds.), GeneReviews\u00ae, Last Updated: March 26, 2015. (\u00a9 1993\u20132017 University of Washington, Seattle, WA.)"},{"key":"10.1016\/j.ymgme.2017.06.001_bb0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2017.06.001_bb0025","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2017.06.001_bb0030","series-title":"ELAPRASE\u00ae Idursulfase Solution, Concentrate","author":"Package insert","year":"2016"},{"key":"10.1016\/j.ymgme.2017.06.001_bb0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ymgmr.2017.01.014","article-title":"Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients","volume":"12","author":"Giugliani","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2017.06.001_bb0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jim.2011.07.020","article-title":"Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease","volume":"373","author":"Sellos-Moura","year":"2011","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ymgme.2017.06.001_bb0045","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00109-008-0309-3","article-title":"Non-inhibitory antibodies impede lysosomal storage reduction during enzyme replacement therapy of a lysosomal storage disease","volume":"86","author":"Matzner","year":"2008","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.ymgme.2017.06.001_bb0050","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1006\/mgme.1999.2859","article-title":"Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats","volume":"67","author":"Turner","year":"1999","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.06.001_bb0055","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2017.06.001_bb0060","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ymgme.2015.11.001","article-title":"Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction","volume":"117","author":"Kishnani","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.06.001_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/hon.2391","article-title":"Bortezomib-induced peripheral neuropathy: a genome-wide association study on multiple myeloma patients","author":"Campo","year":"2017","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.ymgme.2017.06.001_bb0070","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fphar.2017.00086","article-title":"Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review","volume":"8","author":"Kerckhove","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymgme.2017.06.001_bb0075","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12026-014-8564-6","article-title":"Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?","volume":"60","author":"Romao","year":"2014","journal-title":"Immunol. Res."},{"key":"10.1016\/j.ymgme.2017.06.001_bb0080","first-page":"101","article-title":"Adverse effects of low dose methotrexate in rheumatoid arthritis patients","volume":"22","author":"Gilani","year":"2012","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"10.1016\/j.ymgme.2017.06.001_bb0085","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ymgmr.2014.11.007","article-title":"Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II","volume":"2","author":"Kim","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2017.06.001_bb0090","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0609.2012.01754.x","article-title":"Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice","volume":"88","author":"Benson","year":"2012","journal-title":"Eur. J. Haematol."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2017.06.001_bb0095","first-page":"S119","article-title":"Immune tolerance induction with high-dose FVIII and pulsed intravenous immunoglobulin","volume":"30","author":"Stiefel","year":"2010","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.ymgme.2017.06.001_bb0100","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ymgme.2013.08.002","article-title":"The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5years and older treated with intravenous idursulfase","volume":"110","author":"Barbier","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.06.001_bb0105","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/clinchem\/35.3.374","article-title":"Diagnostic test for mucopolysaccharidosis. I. Direct method for quantifying excessive urinary glycosaminoglycan excretion","volume":"35","author":"Whitley","year":"1989","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2017.06.001_bb0110","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1093\/clinchem\/35.10.2074","article-title":"Diagnostic test for mucopolysaccharidosis. II. Rapid quantification of glycosaminoglycan in urine samples collected on a paper matrix","volume":"35","author":"Whitley","year":"1989","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2017.06.001_bb0115","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0003-2697(62)90095-7","article-title":"A modified uronic acid carbazole reaction","volume":"4","author":"Bitter","year":"1962","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgme.2017.06.001_bb0120","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/0003-2697(67)90087-5","article-title":"The measurement of urinary mucopolysaccharides","volume":"21","author":"Di Ferrante","year":"1967","journal-title":"Anal. Biochem."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671921730238X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671921730238X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T11:57:23Z","timestamp":1602244643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109671921730238X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":24,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S109671921730238X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.06.001","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}